Saturday, October 1, 2022


Biotechnology News Magazine

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α7β1 integrin activating antibody​ for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD).

These data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference being held June 20‐23, 2022 in Fort Lauderdale, Florida.

The presentation “Increased Laminin Binding Through Integrin Activation Protects Dystrophic Muscle” was presented by Scott Turner, Ph.D., Senior Vice President, Head of Research at Pliant Therapeutics. It highlighted in vitro and in vivo data demonstrating improved cell morphology, tissue organization and muscle function in human cells and D2-MDX mice after treatment with PLN-101325. Importantly, results showed significant improvements in diaphragm muscle strength and respiratory function.

“Our novel approach of employing an allosteric activating antibody to increase laminin adhesion of muscle cells, could reduce the ongoing muscle injury and potentially enhance regeneration in muscular dystrophy patients,” said Dr. Turner. “The increased diaphragm strength and function seen in D2-MDX mice treated with PLN-101325 highlight the potential of this novel therapy to treat a leading cause of death in muscular dystrophy patients.”

Progressive loss of muscle mass and strength, including respiratory muscle strength, has been observed in muscular dystrophy, contributing to death from respiratory insufficiency. The α7β1​ integrin is a laminin receptor located on the muscle cell surface that is upregulated in muscular dystrophy patients, serving as a compensatory muscle stabilization mechanism. Activating the α7β1​ integrin may help stabilize the muscle membrane, increase muscle strength, and decrease muscle damage. Because α7β1​ can compensate for the loss of the dystroglycan complex, this mechanism has the potential to be combined with existing therapies, as well as those currently in development.

A copy of this presentation can be found on the Publications page under the Posters & Presentations section of the Pliant website.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine